{"id":2167,"date":"2019-03-27T23:26:27","date_gmt":"2019-03-27T23:26:27","guid":{"rendered":"http:\/\/www.phoenixreslabs.com\/?p=2167"},"modified":"2026-04-02T17:51:04","modified_gmt":"2026-04-02T17:51:04","slug":"phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration","status":"publish","type":"post","link":"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/","title":{"rendered":"Phoenix MICRON\u00ae<\/span> CNV System used to test a novel treatment for age-related macular degeneration"},"content":{"rendered":"

In their paper, \u201cSuppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy,\u201d Askou et al develop an adeno-associated virus (AAV) treatment for age-related macular degeneration. Beautiful fluorescent fundoscopy performed with the Phoenix MICRON\u00ae<\/span> validated the success of the subretinal AAV injection, while precise choroidal neovascularization (CNV) induced by Phoenix laser burns confirmed that the AAV does, indeed, decrease neovascularization.<\/p>\n

\"Figure<\/a>
Figure 1. Phoenix MICRON\u00ae<\/span> fluorescent fundus images. The circle shows the area of the retina imaged, while the green areas are the subretinal injections of the AAV. The first row is the AAV with no active elements. The second row is the AAV with micro RNA against VEGFA. The third row has the micro RNA against VEGFA as well as coding for PEDF, an anti-angiogenesis factor<\/figcaption><\/figure>\n

Age-related macular degeneration leads to a crippling loss of vision through an overabundance of choroidal blood vessels. While there are limited treatments, more treatments and a cure are necessary.\u00a0 CNV induced by retinal laser burns in mice is used as the animal model of the disease; treatments that decrease laser burn-induced CNV are candidates for clinical treatments. The Phoenix laser is image guided and easy to use; a crisp fundus image and laser aiming beam allow for precise delivery of the laser burns and subsequent development of CNV.<\/p>\n

\"igure<\/a>
Figure 2. Retinas showing GFP expression (A) were confirmed to have micro RNAs against VEGFA through qPCR and presence of PEDF through western blotting (B).<\/figcaption><\/figure>\n

Askou et al developed two AAV; one contained microRNAs against vascular endothelial growth factor A (VEGFA), which mediates new blood vessel growth, and one also contained pigment endothelial-derived factor (PEDF) which decreases new blood vessel growth. Since the AAV also contained GFP, the Phoenix MICRON\u00ae<\/span> fluorescent fundus images clearly showed where the virus was expressed in the retina (Figure 1). GFP expression was correlated with the anti-VEGFA micro RNAs and PEDF expression through qPCR and western blotting (Figure 2).<\/p>\n

\"Figure<\/a>
Figure 3. Experimental procedure. 50 days after subretinal AAV injection, GFP expression was confirmed and laser burns performed with the Phoenix laser system outside the GFP area. Seven days later, retinas were excised and area analysis performed.<\/figcaption><\/figure>\n

As Figure 3 shows, 50 days after AAV-injection, CNV was induced by using the Phoenix laser system by burning 50 micrometer spots in the retinal areas not affected by the AAV. Seven days later, retinas were excised and analyzed for CNV area and VEGFA levels. Askou et al found a significant decrease in CNV areas with both of the AAV, with a slightly larger decrease with the microRNA plus PEDF (45% for both vs 34% for one). VEGFA levels were decreased markedly by both AAV as well.<\/p>\n

In the discussion, the researchers sum up their work thusly:<\/p>\n

\u201cIn this study, we show that incorporation of the multigenic expression cassette into the AAV plasmid leads to the following: (1) expression of multiple proteins, including PEDF, in vitro following the transfection of relevant mammalian cells; (2) a high level of reporter gene expression in RPE cells following a single subretinal injection in mice; (3) co-expression of miRNA(5,B,7) and PEDF in eyes injected with multigenic AAV\/miR(5,B,7)-PEDF-PE vectors; (4) reduced CNV formation in eyes treated with AAV vectors encoding therapeutic cassettes (AAV\/miR(5,B,7)-AsR-PE and AAV\/miR(5,B,7)-PEDFPE); and (5) an increased, albeit not statistically significant, efficacy due to combined expression of multiple antiangiogenic molecules (anti-VEGFA miRNAs and PEDF) from the same vector.\u201d<\/p>\n

The Phoenix MICRON\u00ae<\/span> furthered their research by enabling points 2-3 with fundus imaging of the subretinal injections, and the Phoenix laser helped point 4 by easy induction of CNV through laser burns.<\/p>\n

Askou, AL, Alsing S, Benckendorff, JNE, Holmgaard, A, Mikkelsen, JG, Aagaard, L, Bek, T, Corydon, TJ. (2019). Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy. Mol Ther Nucleic Acids. 16:38-50. doi: 10.1016\/j.omtn.2019.01.012<\/p>\n","protected":false},"excerpt":{"rendered":"

In their paper, \u201cSuppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy,\u201d Askou et al develop an adeno-associated virus (AAV) treatment for age-related macular degeneration. Beautiful fluorescent fundoscopy performed with the Phoenix MICRON\u00ae validated the success of the subretinal AAV injection, while precise choroidal neovascularization (CNV) induced by Phoenix laser burns confirmed that the […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[331,332,292],"tags":[1009,968,1010,1011,987,336,1012,383,1013,1014],"class_list":["post-2167","post","type-post","status-publish","format-standard","hentry","category-micron-iv","category-ptom","category-non-categorise","tag-aav-therapie-genique-a-double-action","tag-amd","tag-cnv","tag-expression-de-la-gfp","tag-laser","tag-ptom","tag-pedf","tag-phoenix-micron","tag-arn","tag-vegfa"],"acf":[],"yoast_head":"\nPhoenix MICRON\u00ae CNV System used to test a novel treatment for age-related macular degeneration - Phoenix-micron<\/title>\n<meta name=\"description\" content=\"Beautiful fluorescent fundoscopy performed with the Phoenix MICRON validated the success of the subretinal AAV injection, while precise choroidal neovascularization (CNV) induced by Phoenix laser burns confirmed that the AAV does, indeed, decrease neovascularization.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Phoenix MICRON\u00ae CNV System used to test a novel treatment for age-related macular degeneration - Phoenix-micron\" \/>\n<meta property=\"og:description\" content=\"Beautiful fluorescent fundoscopy performed with the Phoenix MICRON validated the success of the subretinal AAV injection, while precise choroidal neovascularization (CNV) induced by Phoenix laser burns confirmed that the AAV does, indeed, decrease neovascularization.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/\" \/>\n<meta property=\"og:site_name\" content=\"Phoenix-micron\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-27T23:26:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-02T17:51:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/phoenixmicron.com\/wp-content\/uploads\/2019\/03\/Screen-Shot-2019-03-27-at-3.27.07-PM.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1302\" \/>\n\t<meta property=\"og:image:height\" content=\"872\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Phoenix-Micron Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Phoenix-Micron Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/\"},\"author\":{\"name\":\"Phoenix-Micron Team\",\"@id\":\"https:\/\/phoenixmicron.com\/fr\/#\/schema\/person\/cffed094aef7226545ce64624bd9b6fa\"},\"headline\":\"Phoenix MICRON\u00ae CNV System used to test a novel treatment for age-related macular degeneration\",\"datePublished\":\"2019-03-27T23:26:27+00:00\",\"dateModified\":\"2026-04-02T17:51:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/\"},\"wordCount\":654,\"publisher\":{\"@id\":\"https:\/\/phoenixmicron.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/phoenixmicron.com\/wp-content\/uploads\/2019\/03\/Screen-Shot-2019-03-27-at-3.27.07-PM-300x201.png\",\"keywords\":[\"AAV Th\u00e9rapie g\u00e9nique \u00e0 double action\",\"AMD\",\"CNV\",\"Expression de la GFP\",\"Laser\",\"PTOM\",\"PEDF\",\"Phoenix MICRON\",\"ARN\",\"VEGFA\"],\"articleSection\":[\"Micron IV\",\"PTOM\",\"Non cat\u00e9goris\u00e9\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/\",\"url\":\"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/\",\"name\":\"Phoenix MICRON\u00ae CNV System used to test a novel treatment for age-related macular degeneration - Phoenix-micron\",\"isPartOf\":{\"@id\":\"https:\/\/phoenixmicron.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/phoenixmicron.com\/wp-content\/uploads\/2019\/03\/Screen-Shot-2019-03-27-at-3.27.07-PM-300x201.png\",\"datePublished\":\"2019-03-27T23:26:27+00:00\",\"dateModified\":\"2026-04-02T17:51:04+00:00\",\"description\":\"Beautiful fluorescent fundoscopy performed with the Phoenix MICRON validated the success of the subretinal AAV injection, while precise choroidal neovascularization (CNV) induced by Phoenix laser burns confirmed that the AAV does, indeed, decrease neovascularization.\",\"breadcrumb\":{\"@id\":\"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/#primaryimage\",\"url\":\"https:\/\/phoenixmicron.com\/wp-content\/uploads\/2019\/03\/Screen-Shot-2019-03-27-at-3.27.07-PM-300x201.png\",\"contentUrl\":\"https:\/\/phoenixmicron.com\/wp-content\/uploads\/2019\/03\/Screen-Shot-2019-03-27-at-3.27.07-PM-300x201.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/phoenixmicron.com\/fr\/phoenix-micron\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Phoenix MICRON\u00ae CNV System used to test a novel treatment for age-related macular degeneration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/phoenixmicron.com\/fr\/#website\",\"url\":\"https:\/\/phoenixmicron.com\/fr\/\",\"name\":\"Phoenix-micron\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/phoenixmicron.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/phoenixmicron.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/phoenixmicron.com\/fr\/#organization\",\"name\":\"Phoenix-micron\",\"url\":\"https:\/\/phoenixmicron.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/phoenixmicron.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/phoenixmicron.com\/wp-content\/uploads\/2019\/04\/faviconlogo.png\",\"contentUrl\":\"https:\/\/phoenixmicron.com\/wp-content\/uploads\/2019\/04\/faviconlogo.png\",\"width\":200,\"height\":200,\"caption\":\"Phoenix-micron\"},\"image\":{\"@id\":\"https:\/\/phoenixmicron.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/phoenixmicron.com\/fr\/#\/schema\/person\/cffed094aef7226545ce64624bd9b6fa\",\"name\":\"Phoenix-Micron Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/bf26b6ffbfc6145dcb9b0af2a88317a138f46f1cd51e55eab23daba4363203b2?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bf26b6ffbfc6145dcb9b0af2a88317a138f46f1cd51e55eab23daba4363203b2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bf26b6ffbfc6145dcb9b0af2a88317a138f46f1cd51e55eab23daba4363203b2?s=96&d=mm&r=g\",\"caption\":\"Phoenix-Micron Team\"},\"url\":\"https:\/\/phoenixmicron.com\/fr\/author\/cvanhoverphoenixtechnologygroup-com\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Phoenix MICRON\u00ae CNV System used to test a novel treatment for age-related macular degeneration - Phoenix-micron","description":"Beautiful fluorescent fundoscopy performed with the Phoenix MICRON validated the success of the subretinal AAV injection, while precise choroidal neovascularization (CNV) induced by Phoenix laser burns confirmed that the AAV does, indeed, decrease neovascularization.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/","og_locale":"fr_FR","og_type":"article","og_title":"Phoenix MICRON\u00ae CNV System used to test a novel treatment for age-related macular degeneration - Phoenix-micron","og_description":"Beautiful fluorescent fundoscopy performed with the Phoenix MICRON validated the success of the subretinal AAV injection, while precise choroidal neovascularization (CNV) induced by Phoenix laser burns confirmed that the AAV does, indeed, decrease neovascularization.","og_url":"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/","og_site_name":"Phoenix-micron","article_published_time":"2019-03-27T23:26:27+00:00","article_modified_time":"2026-04-02T17:51:04+00:00","og_image":[{"width":1302,"height":872,"url":"https:\/\/phoenixmicron.com\/wp-content\/uploads\/2019\/03\/Screen-Shot-2019-03-27-at-3.27.07-PM.png","type":"image\/png"}],"author":"Phoenix-Micron Team","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Phoenix-Micron Team","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/#article","isPartOf":{"@id":"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/"},"author":{"name":"Phoenix-Micron Team","@id":"https:\/\/phoenixmicron.com\/fr\/#\/schema\/person\/cffed094aef7226545ce64624bd9b6fa"},"headline":"Phoenix MICRON\u00ae CNV System used to test a novel treatment for age-related macular degeneration","datePublished":"2019-03-27T23:26:27+00:00","dateModified":"2026-04-02T17:51:04+00:00","mainEntityOfPage":{"@id":"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/"},"wordCount":654,"publisher":{"@id":"https:\/\/phoenixmicron.com\/fr\/#organization"},"image":{"@id":"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/#primaryimage"},"thumbnailUrl":"https:\/\/phoenixmicron.com\/wp-content\/uploads\/2019\/03\/Screen-Shot-2019-03-27-at-3.27.07-PM-300x201.png","keywords":["AAV Th\u00e9rapie g\u00e9nique \u00e0 double action","AMD","CNV","Expression de la GFP","Laser","PTOM","PEDF","Phoenix MICRON","ARN","VEGFA"],"articleSection":["Micron IV","PTOM","Non cat\u00e9goris\u00e9"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/","url":"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/","name":"Phoenix MICRON\u00ae CNV System used to test a novel treatment for age-related macular degeneration - Phoenix-micron","isPartOf":{"@id":"https:\/\/phoenixmicron.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/#primaryimage"},"image":{"@id":"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/#primaryimage"},"thumbnailUrl":"https:\/\/phoenixmicron.com\/wp-content\/uploads\/2019\/03\/Screen-Shot-2019-03-27-at-3.27.07-PM-300x201.png","datePublished":"2019-03-27T23:26:27+00:00","dateModified":"2026-04-02T17:51:04+00:00","description":"Beautiful fluorescent fundoscopy performed with the Phoenix MICRON validated the success of the subretinal AAV injection, while precise choroidal neovascularization (CNV) induced by Phoenix laser burns confirmed that the AAV does, indeed, decrease neovascularization.","breadcrumb":{"@id":"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/#primaryimage","url":"https:\/\/phoenixmicron.com\/wp-content\/uploads\/2019\/03\/Screen-Shot-2019-03-27-at-3.27.07-PM-300x201.png","contentUrl":"https:\/\/phoenixmicron.com\/wp-content\/uploads\/2019\/03\/Screen-Shot-2019-03-27-at-3.27.07-PM-300x201.png"},{"@type":"BreadcrumbList","@id":"https:\/\/phoenixmicron.com\/fr\/phoenix-micron-cnv-system-used-to-test-a-novel-treatment-for-age-related-macular-degeneration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/phoenixmicron.com\/fr\/phoenix-micron\/"},{"@type":"ListItem","position":2,"name":"Phoenix MICRON\u00ae CNV System used to test a novel treatment for age-related macular degeneration"}]},{"@type":"WebSite","@id":"https:\/\/phoenixmicron.com\/fr\/#website","url":"https:\/\/phoenixmicron.com\/fr\/","name":"Phoenix-micron","description":"","publisher":{"@id":"https:\/\/phoenixmicron.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/phoenixmicron.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/phoenixmicron.com\/fr\/#organization","name":"Phoenix-micron","url":"https:\/\/phoenixmicron.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/phoenixmicron.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/phoenixmicron.com\/wp-content\/uploads\/2019\/04\/faviconlogo.png","contentUrl":"https:\/\/phoenixmicron.com\/wp-content\/uploads\/2019\/04\/faviconlogo.png","width":200,"height":200,"caption":"Phoenix-micron"},"image":{"@id":"https:\/\/phoenixmicron.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/phoenixmicron.com\/fr\/#\/schema\/person\/cffed094aef7226545ce64624bd9b6fa","name":"Phoenix-Micron Team","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/bf26b6ffbfc6145dcb9b0af2a88317a138f46f1cd51e55eab23daba4363203b2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bf26b6ffbfc6145dcb9b0af2a88317a138f46f1cd51e55eab23daba4363203b2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bf26b6ffbfc6145dcb9b0af2a88317a138f46f1cd51e55eab23daba4363203b2?s=96&d=mm&r=g","caption":"Phoenix-Micron Team"},"url":"https:\/\/phoenixmicron.com\/fr\/author\/cvanhoverphoenixtechnologygroup-com\/"}]}},"_links":{"self":[{"href":"https:\/\/phoenixmicron.com\/fr\/wp-json\/wp\/v2\/posts\/2167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/phoenixmicron.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/phoenixmicron.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/phoenixmicron.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/phoenixmicron.com\/fr\/wp-json\/wp\/v2\/comments?post=2167"}],"version-history":[{"count":0,"href":"https:\/\/phoenixmicron.com\/fr\/wp-json\/wp\/v2\/posts\/2167\/revisions"}],"wp:attachment":[{"href":"https:\/\/phoenixmicron.com\/fr\/wp-json\/wp\/v2\/media?parent=2167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/phoenixmicron.com\/fr\/wp-json\/wp\/v2\/categories?post=2167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/phoenixmicron.com\/fr\/wp-json\/wp\/v2\/tags?post=2167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}